Savendahl L, Polak M, Backeljauw P, et al. - This study was carried out to evaluate the long-term safety of growth hormone (GH) treatment in clinical practice. Researchers conducted two multicenter longitudinal observational studies: NordiNet International Outcome Study (2006–2016, Europe) and ANSWER Program (2002–2016, USA). The study population consisted of 37,702 patients (68.4% in low-risk, 27.5% in intermediate-risk, and 4.1% in high-risk groups) and 130,476 patient-years of exposure. No indication of increased mortality risk nor adverse events incidence related to GH dose was found in any risk group.